ASH 2024 Archives - Medical Conferences

Home > Haematology > ASH 2024

American Society of Hematology
07–10 December 2024
San Diego, USA

Featured articles

ASH 2024 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

Conference

ASH 2024

18 December 2024 15:33

AQUILA: Early intervention with daratumumab extends survival in smouldering MM

Presented By

Dr Meletios Dimopoulos, University of Athens, Greece

Trial

Phase 3, AQUILA

Conference

ASH 2024

Type

News article

11 December 2024 10:25

New standard-of-care for paediatric B-cell ALL

Presented By

Dr Rachel Rau, University of Washington, WA, USA

Trial

Phase 3, AALL1731

Conference

ASH 2024

Type

News article

10 December 2024 09:36

Online First

Full-dose or reduced-dose DOACs in high-risk VTE on extended therapy?

Presented By

Prof. Francis Couturaud, Brest University Hospital, France

Trial

Phase 3, RENOVE

Conference

ASH 2024

Type

News article

12 December 2024 11:49

IFM2017-03: Daratumumab therapy fruitful for frail patients with MM

Presented By

Prof. Salomon Manier, University of Lille, France

Trial

Phase 3, IFM2017-03

Conference

ASH 2024

Type

News article

12 December 2024 11:41

InMIND: Novel standard-of-care for relapsed or refractory follicular lymphoma?

Presented By

Dr Laurie Sehn, The University of British Columbia, Canada

Trial

Phase 3, inMIND

Conference

ASH 2024

Type

News article

12 December 2024 11:37

Can we omit auto-SCT in patients with mantle cell lymphoma with undetectable MRD post-induction?

Presented By

Dr Timothy Fenske, Medical College of Wisconsin, WI, USA

Trial

Phase 3, EA4151

Conference

ASH 2024

Type

News article

12 December 2024 11:23

Allo-SCT improves lives of children with sickle cell anaemia and abnormal cerebral artery velocities

Presented By

Dr Francoise Bernaudin, Centre Hospitalier Intercommunal Creteil, France

Trial

DREPAGREFFE-2

Conference

ASH 2024

Type

News article

12 December 2024 11:21

ATALANTA-1: Promising data for novel CAR T-cell therapy

Presented By

Dr Marie José Kersten, Amsterdam University Medical Center, the Netherlands

Trial

Phase 1/2, ATALANTA-1

Conference

ASH 2024

Type

News article

11 December 2024 10:29

Findings from phase 3 uproleselan study in AML not all negative

Presented By

Dr Daniel DeAngelo, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3

Conference

ASH 2024

Type

News article

11 December 2024 10:28

Emerging mezigdomide-based options for heavily pre-treated MM

Presented By

Prof. Luciano Costa, University of Alabama at Birmingham, AL, USA

Trial

Phase 1/2, CA057-003

Conference

ASH 2024

Type

News article

11 December 2024 10:27

AQUILA: Early intervention with daratumumab extends survival in smouldering MM

Presented By

Dr Meletios Dimopoulos, University of Athens, Greece

Trial

Phase 3, AQUILA

Conference

ASH 2024

Type

News article

11 December 2024 10:25

ZUMA-5: Curative potential of axi-cel in follicular lymphoma

Presented By

Dr Sattva Neelapu, MD Anderson Cancer Center, TX, USA

Trial

Phase 3, ZUMA-5

Conference

ASH 2024

Type

News article

11 December 2024 10:24

CEPHEUS: Further support for daratumumab-regimens in untreated MM

Presented By

Prof. Sonja Zweegman, Amsterdam University Medical Centre, the Netherlands

Trial

Phase 3, CEPHEUS

Conference

ASH 2024

Type

News article

10 December 2024 09:39

New standard-of-care for paediatric B-cell ALL

Presented By

Dr Rachel Rau, University of Washington, WA, USA

Trial

Phase 3, AALL1731

Conference

ASH 2024

Type

News article

10 December 2024 09:36

PIVOT: Can hydroxyurea improve outcomes in HbSC?

Presented By

Dr Yvonne Dei-Adomakoh, Korle-bu Teaching Hospital, Ghana

Trial

Phase 2, PIVOT

Conference

ASH 2024

Type

News article

10 December 2024 09:32

Menin inhibitors on the rise in KMT2Ar acute leukaemia

Presented By

Dr Ibrahim Aldoss, City of Hope, CA, USA

Trial

Phase 2, AUGMENT-101

Conference

ASH 2024

Type

News article

10 December 2024 09:30

LUNA 3: Rilzabrutinib meets primary endpoint in ITP

Presented By

Dr David Kuter, Massachusetts General Hospital, MA, USA

Trial

Phase 3, LUNA 3

Conference

ASH 2024

Type

News article

10 December 2024 09:28

Featured articles

CONTENTS

Online First